Selecting a PARP Inhibitor for Front Line Maintenance in Advance Ovarian Cancer

Niraparib/dostarlimab with platinum-therapy met its PFS end point in patients with advanced ovarian cancer in the phase 3 FIRST-ENGOT-OV44 trial.

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.

Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.

Updated findings from RAMP 201 show that avutometinib/defactinib is generally well tolerated among those with low-grade serous ovarian cancer.

Combining IMNN-001 with chemotherapy also elicited a progression-free survival improvement compared with chemotherapy alone in the OVATION 2 trial.